EBR Systems, Inc., (ASX: EBR) based in Sunnyvale, California, presents its 2023 Appendix 4E Preliminary Final Report. Key operational achievements include meeting primary trial endpoints for the SOLVE-CRT study, affirming the effectiveness of the WiSE® CRT System for heart failure patients. Leadership enhancements include the appointment of Dr. Rick Kuntz as Chief Scientific Officer and Mr. Gary Doherty as Chief Financial Officer.
Financially, operational expenses increased slightly due to heightened R&D and administrative spending, offset by reductions elsewhere. EBR secured funding for regulatory activities and initial commercial launch, along with notable appearances in global scientific and investor conferences. Positive trial results pave the way for FDA approval, with submission targeted for Q3 2024 and approval expected in Q1 2025. The company anticipates continued growth with its strengthened team and financial backing.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 21, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
